Aadi Bioscience Q3 Loss Per Share Narrows

November 08, 2023 — 08:46 am EST

Written by RTTNews.com for RTTNews

(RTTNews) - Aadi Bioscience, Inc. (AADI) Wednesday reported loss for the third quarter on higher expenses, wider than the prior year. However, on a per-share basis, loss was narrower than the prior year. Revenues for the quarter improved from the previous year.

Further, the company focused on precision therapies for genetically defined cancers with alterations in mTOR pathway genes, said it expects to present an early interim analysis of PRECISION 1 trial of nab-sirolimus in solid tumors with TSC1 or TSC2 inactivating alterations by mid-December.

The quarterly loss was $16.302 million, compared to loss of $14.474 million last year. On a per-share basis, loss narrowed to $0.60 from $0.68 a year ago.

On average, 5 analysts polled by Thomson Reuters expected the company to report loss of $0.72 per share. Analysts estimates usually exclude special items.

Revenue for the quarter increased to $5.96 million from $4.25 million a year ago. Analysts were looking for $6.61 million.

RTTNews

Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

Aadi Bioscience Q3 Loss Per Share Narrows

Tags

Latest Articles